Soluble Receptor for Advanced Glycation End-product (sRAGE)/pentosidine Ratio: a Potential Risk Factor Determinant for Type 2 Diabetic Retinopathy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2013 Apr 5

PMID 23552832

Citations 9

Authors

Zhi Xiang Ng

Kek Heng Chua

Tajunisah Iqbal

Umah Rani Kuppusamy

Affiliations

Soon will be listed here.

Abstract

This study aims to investigate potential diabetic retinopathy (DR) risk factors by evaluating the circulating levels of pentosidine, soluble receptor for advanced glycation end-product (sRAGE), advanced oxidation protein product (AOPP) as well as glutathione peroxidase (GPx) and superoxide dismutase (SOD) activities in DR patients. A total of 235 healthy controls, 171 type 2 diabetic without retinopathy (DNR) and 200 diabetic retinopathy (DR) patients were recruited. Plasma was extracted for the estimation of pentosidine, sRAGE, AOPP levels and GPx activity whereas peripheral blood mononuclear cells were disrupted for SOD activity measurement. DNR and DR patients showed significantly higher levels of plasma pentosidine, sRAGE and AOPP but lower GPx and SOD activities when compared to healthy controls. The sRAGE/pentosidine ratio in DR patients was significantly lower than the ratio detected in DNR patients. Proliferative DR patients had significantly higher levels of plasma pentosidine, sRAGE, AOPP and sRAGE/pentosidine ratio than non-proliferative DR patients. High HbA1c level, long duration of diabetes and low sRAGE/pentosidine ratio were determined as the risk factors for DR. This study suggests that sRAGE/pentosidine ratio could serve as a risk factor determinant for type 2 DR as it has a positive correlation with the severity of DR.

Citing Articles

Effect of miR-27b-3p and Nrf2 in human retinal pigment epithelial cell induced by high-glucose.

Lai Q, Xie T, Zheng W, Huang Y Int J Ophthalmol. 2023; 16(10):1582-1588.

PMID: 37854382 PMC: 10559042. DOI: 10.18240/ijo.2023.10.04.

Circulating Biomarkers to Predict Diabetic Retinopathy in Patients with Diabetic Kidney Disease.

Jonny , Violetta L, Kartasasmita A, Supriyadi R, Rita C Vision (Basel). 2023; 7(2).

PMID: 37092467 PMC: 10123608. DOI: 10.3390/vision7020034.

Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications.

Mengstie M, Abebe E, Teklemariam A, Mulu A, Agidew M, Teshome Azezew M Front Mol Biosci. 2022; 9:1002710.

PMID: 36188225 PMC: 9521189. DOI: 10.3389/fmolb.2022.1002710.

Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.

Lee J, Yun J, Ko S Nutrients. 2022; 14(15).

PMID: 35956261 PMC: 9370094. DOI: 10.3390/nu14153086.

Receptors of Advanced Glycation End Product (RAGE) Suppression Associated With a Preserved Osteogenic Differentiation in Patients With Prediabetes.

Phimphilai M, Pothacharoen P, Chattipakorn N, Kongtawelert P Front Endocrinol (Lausanne). 2022; 13:799872.

PMID: 35237235 PMC: 8882829. DOI: 10.3389/fendo.2022.799872.

References

Mates J, Perez-Gomez C, Nunez de Castro I . Antioxidant enzymes and human diseases. Clin Biochem. 2000; 32(8):595-603. DOI: 10.1016/s0009-9120(99)00075-2. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Boyum A . Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl. 1968; 97:7. View

. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):823-33. View

Forbes J, Thorpe S, Thallas-Bonke V, Pete J, Thomas M, Deemer E . Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005; 16(8):2363-72. DOI: 10.1681/ASN.2005010062. View

Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux J . Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem. 2005; 51(9):1749-50. DOI: 10.1373/clinchem.2005.051961. View

Costagliola C . Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vivo and in vitro study. Clin Physiol Biochem. 1990; 8(4):204-10. View

Droge W . Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82(1):47-95. DOI: 10.1152/physrev.00018.2001. View

Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Nguyen A, Zingraff J, Jungers P . Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49(5):1304-13. DOI: 10.1038/ki.1996.186. View

10.

Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, Tesar V . Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant. 2007; 22(7):2020-6. DOI: 10.1093/ndt/gfm050. View

11.

Salman A, Mansour D, Swelem A, Al-Zawahary W, Radwan A . Pentosidine - a new biochemical marker in diabetic retinopathy. Ophthalmic Res. 2009; 42(2):96-8. DOI: 10.1159/000225661. View

12.

Stitt A . AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010; 51(10):4867-74. DOI: 10.1167/iovs.10-5881. View

13.

Kalousova M, Sulkova S, Fialova L, Soukupova J, Malbohan I, Spacek P . Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant. 2003; 18(12):2577-81. DOI: 10.1093/ndt/gfg404. View

14.

Kankova K, Marova I, ZAHEJSKY J, Muzik J, Stejskalova A, Znojil V . Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism. 2001; 50(10):1152-60. DOI: 10.1053/meta.2001.26757. View

15.

. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786-806. View

16.

Nazratun N, Mahmood A, Kuppusamy U, Ahmad T, Tan S . Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2007; 11(4):245-50. DOI: 10.1177/1358863x06072202. View

17.

Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Nguyen A, Canteloup S, Dayer J . Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998; 161(5):2524-32. View

18.

Nakamura K, Yamagishi S, Matsui T, Adachi H, Takeuchi M, Imaizumi T . Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2008; 7(4):188-90. DOI: 10.1007/s10238-007-0146-7. View

19.

Valko M, Leibfritz D, Moncol J, Cronin M, Mazur M, Telser J . Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2006; 39(1):44-84. DOI: 10.1016/j.biocel.2006.07.001. View

20.

Grossin N, Wautier M, Meas T, Guillausseau P, Massin P, Wautier J . Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008; 34(4 Pt 1):392-5. DOI: 10.1016/j.diabet.2008.04.003. View